Impact of Direct Acting Antiviral Drugs (DAADs) on Cognitive and Sleep Dysfunction among Hepatitis C Virus Infected Patients

Abstract

C hronic hepatitis C virus (HCV) is a major cause of liver- related morbidity and mortality WHO 2015 estimates that in 2015, 71 million persons were living with chronic hepatitis C virus (HCV) infection worldwide and that 399 000 died from cirrhosis or hepatocellular carcinoma caused by HCV infection. WHO 2016, the World Health Assembly endorsed the Global Health Sector Strategy (GHSS) on viral hepatitis, which proposes to eliminate viral hepatitis as a public health threat by 2030 (90% reduction in incidence and 65% reduction in mortality). Elimination of viral hepatitis as a public health threat requires 90% of those infected to be diagnosed and 80% of those diagnosed to be treated.